Detalles de la búsqueda
1.
Direct and selective pharmacological disruption of the YAP-TEAD interface by IAG933 inhibits Hippo-dependent and RAS-MAPK-altered cancers.
Nat Cancer
; 2024 Apr 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-38565920
2.
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Cell Rep
; 42(4): 112297, 2023 04 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36961816
3.
Capmatinib (INC280) Is Active Against Models of Non-Small Cell Lung Cancer and Other Cancer Types with Defined Mechanisms of MET Activation.
Clin Cancer Res
; 25(10): 3164-3175, 2019 05 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30674502
4.
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma.
Cancer Discov
; 7(3): 252-263, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28034880
Resultados
1 -
4
de 4
1
Próxima >
>>